EUVIMEDEUVIMED entdecken
Crossref

EGCG enhances antitumor effect of apatinib in nonsmall cell lung cancer by targeting VEGF signaling to inhibit glycolysis

Yue Zhou iD, Liqing Qin, Chengpeng Li, Danxue Zhu, Bo Liu

Drug Development Research · 2024

DOI: 10.1002/ddr.22239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2024. Verfasst von Yue Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Guizhou University, Guiyang, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Catechin, Glycolysis, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Synthesis of flavonol derivatives and the mechanism of combined administration in the treatment of chronic myelogenous leukemia Innovation and Entrepreneurship…, Laboratory Opening Project of Guizhou University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nonsmall cell lung cancer (NSCLC), one of the most aggressive malignancies globally, is characterized by poor prognosis and limited life expectancy. Epigallocatechin‐3‐gallate (EGCG), a natural polyphenol found in green tea, has emerged as a promising anticancer agent due to its potent antitumor properties. However, the role and the underlying mechanisms of EGCG in NSCLC remain poorly understood. Hence, this research aimed to explore the effect of EGCG on the antitumor effect of apatinib in NSCLC through vascular endothelial growth factor (VEGF)‐regulated glycolysis. Cell Counting Kit‐8 (CCK‐8), 5‐ethynyl‐2'‐deoxyuridine staining, wound healing, transwell, terminal deoxynucleotidyl transferase dUTP nick‐end labeling, and flow cytometry assays were carried out to evaluate the proliferation, migration, invasion, and apoptosis of H1299 cells, respectively. Furthermore, western blot analysis was used to detect the expressions of VEGF, p‐vascular endothelial growth factor receptor‐2, hypoxia‐inducible factor 1α, neuropilin‐1, phosphorylated‐phosphatidylinositol 3‐kinase, and phosphorylated‐AKT. The transfection efficiency of H1299 cells with VEGF overexpression plasmid was also assessed by western blot analysis. Glycolysis was analyzed by estimating extracellular acidification rate, lactate concentration, glucose uptake, and the expressions of lactate dehydrogenase A, pyruvate kinase M2, and hexokinase 2. The results demonstrated that VEGF activated glycolysis in NSCLC cells. EGCG alone and apatinib alone or in combination inhibited cell viability, proliferation, invasion, migration, and glycolysis whereas promoted apoptosis in NSCLC cells. EGCG regulated glycolysis levels in NSCLC through VEGF overexpression, and enhanced the antitumor effect of apatinib in NSCLC through VEGF‐regulated glycolysis. Taken together, EGCG strengthened the protective effects of apatinib in NSCLC through glycolysis mediated by VEGF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCatechinGlycolysisLung NeoplasmsPyridinesVascular Endothelial Growth Factor ASignal TransductionHumansCell Line, TumorCell ProliferationAntineoplastic AgentsApoptosisCell MovementDrug Synergism

Stichwörter der Autor:innen

EGCGNSCLCVEGFapatinibglycolysis

Substanzen

apatinibepigallocatechin gallateCatechinPyridinesVascular Endothelial Growth Factor AAntineoplastic AgentsVEGFA protein, human

Autor:innen und Institutionen

  • College of Pharmacy, Guizhou University, Guiyang, China.
  • Guizhou Engineering Laboratory for Synthetic Drugs, Guizhou University, Guiyang, China.

ORCID-Profile: Yue Zhou

Förderung

  • Synthesis of flavonol derivatives and the mechanism of combined administration in the treatment of chronic myelogenous leukemia Innovation and Entrepreneurship…
  • Laboratory Opening Project of Guizhou University

Zitieren

APA

Zhou, Y., Qin, L., Li, C., Zhu, D., & Liu, B. (2024). EGCG enhances antitumor effect of apatinib in nonsmall cell lung cancer by targeting VEGF signaling to inhibit glycolysis. Drug Development Research. https://doi.org/10.1002/ddr.22239

Vancouver

Zhou Y, Qin L, Li C, Zhu D, Liu B. EGCG enhances antitumor effect of apatinib in nonsmall cell lung cancer by targeting VEGF signaling to inhibit glycolysis. Drug Development Research. 2024. doi:10.1002/ddr.22239

BibTeX
@article{Zhou2024,
  author = {Zhou, Yue and Qin, Liqing and Li, Chengpeng and Zhu, Danxue and Liu, Bo},
  title = {EGCG enhances antitumor effect of apatinib in nonsmall cell lung cancer by targeting VEGF signaling to inhibit glycolysis},
  journal = {Drug Development Research},
  year = {2024},
  doi = {10.1002/ddr.22239}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche